Smith & Nephew (SNN) Return on Capital Employed (2009 - 2024)
Smith & Nephew (SNN) reported Return on Capital Employed of 12.16% for Q4 2024, up 4542.0% on a YoY basis from 0.26% in Q1 2024, and up 136.55% quarter-over-quarter from 33.26% in Q4 2023.
Smith & Nephew (SNN) Return on Capital Employed (2009 - 2024) Analysis & Trends
Smith & Nephew has reported Return on Capital Employed for 14 years, with the latest figure at 12.16% in Q4 2024.
- For the quarter ending Q4 2024, Return on Capital Employed rose 4542.0% year-over-year to 12.16%; the trailing twelve-month figure through Dec 2024 stood at 12.16% (up 4542.0% YoY), and the FY2025 full-year result was 9.01%, down 899.0% from the prior year.
- Return on Capital Employed for Q4 2024 stood at 12.16%, up from 33.26% in the prior quarter.
- The five-year high for Return on Capital Employed was 38.89% in Q4 2020, with the low at 52.62% in Q4 2022.
- Historically, Return on Capital Employed has averaged 16.63% across 5 years, with a median of 33.26% in 2023.
- Annual changes were most pronounced in 2021 — Return on Capital Employed tumbled 8720 bps — and 2024, when it jumped 4542 bps.
- Smith & Nephew's Return on Capital Employed stood at 38.89% in 2020, then plunged by 224 bps to 48.31% in 2021, then decreased by 9 bps to 52.62% in 2022, then soared by 37 bps to 33.26% in 2023, then jumped by 137 bps to 12.16% in 2024.
- The last three Return on Capital Employed figures came in at 12.16% (Q4 2024), 33.26% (Q4 2023), and 52.62% (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | Smith & Nephew | 5.27 Bn | 4.69 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 12.16% |
| Dec 31, 2023 | -33.26% |
| Dec 31, 2022 | -52.62% |
| Dec 31, 2021 | -48.31% |
| Dec 31, 2020 | 38.89% |
| Dec 31, 2019 | 53.63% |
| Dec 31, 2018 | 65.68% |
| Dec 31, 2017 | 67.32% |
| Dec 31, 2016 | 22.33% |
| Dec 31, 2015 | 20.32% |
| Dec 31, 2014 | 15.14% |
| Mar 31, 2014 | 16.62% |
| Dec 31, 2013 | 17.53% |
| Sep 28, 2013 | 38.65% |
| Mar 31, 2013 | 18.22% |
| Dec 31, 2012 | 18.75% |
| Sep 29, 2012 | 20.62% |
| Jun 30, 2012 | -9,426,542.70% |
| Mar 31, 2012 | 75.12% |
| Dec 31, 2009 | 0.00% |